Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „Combination“
Suchtreffer
Begriffe & Kennungen
Calquence · 4.8 · Calquence in combination with venetoclax and obinutuzumab
Eintrag öffnenCalquence · 4.8 · Of the 223 patients in clinical studies of Calquence in combination of obinutuzumab therapy, 47% were greater
Eintrag öffnenCalquence · 4.8 · Of the 223 patients in clinical studies of Calquence in combination of obinutuzumab, 47% were greater than 65
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, discontinuation of Calquence due
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, discontinuation of Calquence due
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, the most common (≥ 20%) ADRs of a
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, the most common (≥ 20%) ADRs of a
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, 24% were greater t
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, 24% were greater t
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, discontinuation of
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, severe (Grade ≥ 3)
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, severe (Grade ≥ 3)
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, the most common (≥
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, the most common (≥
Eintrag öffnenCalquence · 4.8 · Of the 291 patients treated with Calquence in combination with venetoclax, 28.9% were greater than 65 years an
Eintrag öffnenCalquence · 4.8 · Of the 291 patients treated with Calquence in combination with venetoclax, 28.9% were greater than 65 years an
Eintrag öffnenCalquence · 4.8 · Of the 291 patients treated with Calquence in combination with venetoclax, discontinuation of Calquence due to
Eintrag öffnenCalquence · 4.8 · Of the 291 patients treated with Calquence in combination with venetoclax, discontinuation of Calquence due to
Eintrag öffnenCalquence · 4.8 · Of the 291 patients treated with Calquence in combination with venetoclax, severe (Grade ≥ 3) infections were
Eintrag öffnenCalquence · 4.8 · Of the 291 patients treated with Calquence in combination with venetoclax, severe (Grade ≥ 3) infections were
Eintrag öffnen